The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1469
May 25, 2015
View Complete Issue         Table of Contents 2019 
Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic
May 25, 2015 (Issue: 1469)
The FDA has approved ceftazidime/avibactam (Avycaz – Actavis) for IV treatment of complicated urinary tract and intra-abdominal infections in adults who have limited or no other treatment options. Ceftolozane/tazobactam (Zerbaxa – Cubist),...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Ceftazidime/Avibactam (Avycaz) - A New Intravenous Antibiotic
Article code: 1469c
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.